ClinicalTrials.gg
RecruitingNCT05788341Updated Mar 27, 2024

The Israeli Study for Islet Autoantibodies Screening in Families of Type-1 Diabetes Patients

An observational study in Type 1 Diabetes, sponsored by Rabin Medical Center. Recruiting at 1 site in Israel. Open to participants aged 2 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-27.

Sponsored by Rabin Medical Center · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Cross-sectional
Enrollment
300
Ages
2 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center — 8 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Rabin Medical Center.

Started
2023
the only one that year
Observational
4 of 42
3 open now
Registered
37th of 42
by date

Among the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center, this one is the only one that started in 2023, is one of 4 observational ones, and was the 37th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

8 of the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 2 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center, or all of them as a file.
02

Study summary

We aim at establishing a research program that will offer screening for the presence of Islet Autoantibodies (IA) in relatives of people with Type 1 Diabetes (T1D).

Relatives of people with diabetes, children, and adults from our clinic and all over Israel will be offered to participate in the study. The presence of IA will be evaluated using the Detection by Agglutination-PCR (ADAP) technology developed by Enable Biosciences, which is 1,000-10,000 times more analytically sensitive than currently used methods.. When positive in the screening, multiple antibodies will be confirmed by a second sample analyzed by the ADAP technology and by a radio binding assay (RBA). People positive for one or more antibodies (stage 1 or 2 T1D) will be referred to attend an educational program at our center. This program will include diabetes education emphasizing DKA prevention as well as stress assessment for the families involved and stress alleviating interventions. After the educational visit, people at risk of developing diabetes will be referred to further follow-up and evaluation under routine medical care at our center.

03

Conditions studied

  • Type 1 Diabetes

Keywords

  • Stage 1 diabetes
  • stage 2 diabetes
04

Who can participate

Ages eligible
2 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

First degree relatives of people with TID

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First degree family member (sibling or parent) of a known T1D patient
  • Age 2-45 years
  • Signing an

Exclusion criteria

Exclusion Criteria:

  • Known diabetes of any kind (type 2, MODY)
  • Have a previous history of being treated with insulin or oral diabetes medications.
  • Currently be using systemic agents (topical and inhaled agents are acceptable)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Family-based
Time perspective
Cross-sectional
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Positive Islet Autoantibodies

    Time frame: Screening visit

07

Study locations

1 of 1 sites recruiting
  • Schneider Children Medical Center of Israel
    Petach-Tikva, Israel
    Recruiting
    • Alona Hamou, MSc · Contactalonah@clalit.org.il · 972-545-950-277
    • Moshe Phillip, Prof · Principal investigator
    • Tal Oron, Dr. · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Apr 2025, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2023
First posted
Mar 28, 2023
StartActual
May 30, 2023
Primary completionEst.
Apr 2025
CompletionEst.
Apr 2025
Last update
Mar 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05788341
Responsible party
Sponsor
First posted
Mar 28, 2023
Start date
May 30, 2023
Primary completion
Apr 2025 (estimated)
Completion
Apr 2025 (estimated)
Last update
Mar 27, 2024

Study contacts

Alona Hamou, Msc
Contact
alonah@clalit.org.il
972-545-950277

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion